Immunome Bio (IMNM) - Long-Term Debt to Capital Coefficient
The confirmed price history on the GURU.Markets chart for Immunome, Inc. (IMNM), which has a metric of 0.01, illustrates a business focused on developing immune-based drugs. The firm's competitive advantage is based on a unique method of extracting antibodies from the B-cells of recovered individuals. Strict patent restrictions and lobbyist support in the US hinder market entry, despite rigorous FDA oversight. Risks are mitigated through a portfolio of several independent oncology programs.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_IMNM_-_Immunome-Inc._-_Long-Term-Debt-to-Capital "IMNM: Immunome Long-Term Debt to Capital 07/04/2022 - 10/31/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Immunome, Inc. (IMNM)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
- net income and valuation ratios data:
General company analysis:Immunome Inc - IMNM
For the biopharmaceutical business of Immunome, Inc. (IMNM), the long-term debt-to-equity ratio reflects the financing strategy for antibody development until the company achieves positive free cash flow. This ratio compares liabilities with maturities exceeding one year against shareholders' equity, allowing investors to assess the company's degree of financial autonomy and debt load risks during the scaling of clinical trials.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|gossamerbio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Long-Term Liabilities to Capital|Pieris Pharmaceuticals Inc - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Savara Pharma SVRA|Rigel Pharmaceuticals (RIGL) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio anaptysbio.com|Long-Term Debt to Equity Astria Therapeutics, Inc.|Long-Term Debt to Equity Ratio enGene Holdings Inc (ENGN)|Long-Term Debt to Equity Ratio RAPT (RAPT Therapeutics, Inc.)|Long-Term Debt to Capital aerovatetx.com (JBIO)|Long-Term Debt to Equity Aclaris Therapeutics ACRS|KYTX: Long-Term Debt to Capital Ratio|TLSA - Long-Term Debt to Equity|Long-Term Liabilities to Capital Cabaletta Bio Inc.|Ventyx Bio (VTYX) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Theratechnologies, Inc|AVTX (Avalo Therapeutics, Inc) - Long-Term Debt to Capital|Long-Term Liabilities to Capital eledon.com ELDN|Long-Term Debt to Equity Ratio AGEN (Agenus Inc.)|CLYM (Climb Bio Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ZURA (Zura Bio Limited)|Ratio of Long-Term Indebtedness to Capital aTyr Pharmaceuticals (ATYR)|ADAG - Long-Term Debt to Equity|IMA (ImageneBio Inc) - Long-Term Debt to Capital Ratio|STTK: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Equillium|Long-Term Debt to Equity Ratio CNTB|Immunic Inc (IMUX) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital ATRA|Ratio of Long-Term Indebtedness to Capital inflarx.de|Long-Term Debt to Equity X4 Pharmaceuticals, Inc. XFOR|ACET - Long-Term Debt to Equity Ratio|CELU - Long-Term Debt to Equity|INMB (INmune Bio Corporation) - Long-Term Debt to Capital Ratio|Barinthus Biotherapeutics (BRNS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio kezarlifesciences.com|Long-Term Debt to Equity SAB Biotherapeutics, Inc.|Akari Therapeutics PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital ENLV|QTTB (q32bio.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital GOVX (GeoVax Labs, Inc.)|Long-Term Debt to Capital edesabiotech.com EDSA|IBIO - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CARM (Carisma Therapeutics)|XTL Biopharmaceuticals, Ltd. (XTLB) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Bolt Biotherapeutics, Inc.|HCWB (HCW Biologics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital Aptevo|Long-Term Debt to Equity Ratio AIM (AIM ImmunoTech)|ADTX (aditxt.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital GRI (GRI Bio Corp)|Ratio of Long-Term Indebtedness to Capital XORTX Corp (XRTX)|HIND - Long-Term Debt to Equity|revbiosciences.com (REVB) - Long-Term Debt to Equity Ratio|Indaptus Therapeutics, Inc. (INDP) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Scinai Immunotherapeutics Ltd|Long-Term Debt to Equity Ratio CALI|Long-Term Debt to Capital Affimed Therapeutics|Long-Term Debt to Equity Allakos Inc. (ALLK)|hookipapharma.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital IGMS (IGM Biosciences)|iTeos Therapeutics Inc (ITOS) - Long-Term Liabilities to Capital|Ocean Bio - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital TC BioPharm Ltd TCBP|Third Harmonic Bio (THRD) - Long-Term Debt to Equity